329 related articles for article (PubMed ID: 23566295)
1. B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design.
Reddy V; Jayne D; Close D; Isenberg D
Arthritis Res Ther; 2013; 15 Suppl 1(Suppl 1):S2. PubMed ID: 23566295
[TBL] [Abstract][Full Text] [Related]
2. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.
Harvey PR; Gordon C
BioDrugs; 2013 Apr; 27(2):85-95. PubMed ID: 23456653
[TBL] [Abstract][Full Text] [Related]
3. [Progress in B-cell targeting therapy for the treatment of systemic lupus erythematosus].
Tanaka Y
J UOEH; 2011 Jun; 33(2):173-81. PubMed ID: 21702122
[TBL] [Abstract][Full Text] [Related]
4. Rituximab in systemic lupus erythematosus and lupus nephritis.
Beckwith H; Lightstone L
Nephron Clin Pract; 2014; 128(3-4):250-4. PubMed ID: 25471633
[TBL] [Abstract][Full Text] [Related]
5. B-cell depletion in the treatment of lupus nephritis.
Gregersen JW; Jayne DR
Nat Rev Nephrol; 2012 Sep; 8(9):505-14. PubMed ID: 22801948
[TBL] [Abstract][Full Text] [Related]
6. Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus.
Md Yusof MY; Shaw D; El-Sherbiny YM; Dunn E; Rawstron AC; Emery P; Vital EM
Ann Rheum Dis; 2017 Nov; 76(11):1829-1836. PubMed ID: 28684557
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of biologic therapies for systemic lupus erythematosus treatment: systematic review and meta-analysis.
Borba HH; Wiens A; de Souza TT; Correr CJ; Pontarolo R
BioDrugs; 2014 Apr; 28(2):211-28. PubMed ID: 24190520
[TBL] [Abstract][Full Text] [Related]
8. Targeting B cells in SLE: the experience with rituximab treatment (anti-CD20).
Eisenberg R
Endocr Metab Immune Disord Drug Targets; 2006 Dec; 6(4):345-50. PubMed ID: 17214580
[TBL] [Abstract][Full Text] [Related]
9. Rituximab and lupus--a promising pair?
Ekö SL; van Vollenhoven RF
Curr Rheumatol Rep; 2014; 16(9):444. PubMed ID: 25074032
[TBL] [Abstract][Full Text] [Related]
10. B-cell targeted treatments for lupus: the journey counts as much as the destination.
Falgarone G; Dhote R; Boissier MC
Joint Bone Spine; 2012 Oct; 79(5):437-40. PubMed ID: 22480746
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.
Merrill JT; Neuwelt CM; Wallace DJ; Shanahan JC; Latinis KM; Oates JC; Utset TO; Gordon C; Isenberg DA; Hsieh HJ; Zhang D; Brunetta PG
Arthritis Rheum; 2010 Jan; 62(1):222-33. PubMed ID: 20039413
[TBL] [Abstract][Full Text] [Related]
12. B-cell-targeted therapy for systemic lupus erythematosus.
Sabahi R; Anolik JH
Drugs; 2006; 66(15):1933-48. PubMed ID: 17100405
[TBL] [Abstract][Full Text] [Related]
13. Improving B-cell depletion in systemic lupus erythematosus and rheumatoid arthritis.
Mota P; Reddy V; Isenberg D
Expert Rev Clin Immunol; 2017 Jul; 13(7):667-676. PubMed ID: 27841031
[TBL] [Abstract][Full Text] [Related]
14. Rituximab - The first twenty years.
Leandro M; Isenberg DA
Lupus; 2021 Mar; 30(3):371-377. PubMed ID: 33459161
[TBL] [Abstract][Full Text] [Related]
15. Connective tissue diseases: The conundrum of B cell depletion in SLE.
Sanz I
Nat Rev Rheumatol; 2009 Jun; 5(6):304-5. PubMed ID: 19491910
[TBL] [Abstract][Full Text] [Related]
16. Internalization of rituximab and the efficiency of B Cell depletion in rheumatoid arthritis and systemic lupus erythematosus.
Reddy V; Cambridge G; Isenberg DA; Glennie MJ; Cragg MS; Leandro M
Arthritis Rheumatol; 2015 May; 67(8):2046-55. PubMed ID: 25916583
[TBL] [Abstract][Full Text] [Related]
17. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.
Teng YKO; Bruce IN; Diamond B; Furie RA; van Vollenhoven RF; Gordon D; Groark J; Henderson RB; Oldham M; Tak PP
BMJ Open; 2019 Mar; 9(3):e025687. PubMed ID: 30898822
[TBL] [Abstract][Full Text] [Related]
18. Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis.
Duxbury B; Combescure C; Chizzolini C
Lupus; 2013 Dec; 22(14):1489-503. PubMed ID: 24135078
[TBL] [Abstract][Full Text] [Related]
19. B-cell-targeted therapy for systemic lupus erythematosus: an update.
Ding C; Foote S; Jones G
BioDrugs; 2008; 22(4):239-49. PubMed ID: 18611066
[TBL] [Abstract][Full Text] [Related]
20. Targeted B-cell depletion therapy in childhood-onset systemic lupus erythematosus: progress to date.
Marks SD; Tullus K
Paediatr Drugs; 2007; 9(6):371-8. PubMed ID: 18052407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]